Pharmaceutical

AC Immune wins FDA fast track for Alzheimer’s vaccine candidate

JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.

Jul 26, 2024 - 04:00
AC Immune wins FDA fast track for Alzheimer’s vaccine candidate
JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.
Read the original article

Tags:

Previous Article

Rainfall patterns have become more erratic over the past century: Solid evidence...

Next Article

Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ICR and Royal Marsden NHS Foundation Trust open new integrated pathology unit

ICR and Royal Marsden NHS Foundation Trust open new int...

May 12, 2023

Resilience secures funds to enhance production of essential medicine components

Resilience secures funds to enhance production of essen...

Oct 6, 2024

STAT+: Sophisticated phishing and deepfakes: How generative AI brings new threats for hospitals

STAT+: Sophisticated phishing and deepfakes: How genera...

Jan 30, 2024